190 related articles for article (PubMed ID: 31263710)
41. Leukotriene receptor antagonism with montelukast as a possible therapeutic for venous thromboembolism prophylaxis: An observational study.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Prostaglandins Other Lipid Mediat; 2022 Aug; 161():106649. PubMed ID: 35595009
[TBL] [Abstract][Full Text] [Related]
42. Excessive EP4 Signaling in Smooth Muscle Cells Induces Abdominal Aortic Aneurysm by Amplifying Inflammation.
Hiromi T; Yokoyama U; Kurotaki D; Mamun A; Ishiwata R; Ichikawa Y; Nishihara H; Umemura M; Fujita T; Yasuda S; Minami T; Goda M; Uchida K; Suzuki S; Takeuchi I; Masuda M; Breyer RM; Tamura T; Ishikawa Y
Arterioscler Thromb Vasc Biol; 2020 Jun; 40(6):1559-1573. PubMed ID: 32321307
[TBL] [Abstract][Full Text] [Related]
43. As a potential treatment of COVID-19: Montelukast.
Fidan C; Aydoğdu A
Med Hypotheses; 2020 Sep; 142():109828. PubMed ID: 32416408
[TBL] [Abstract][Full Text] [Related]
44. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Dey M; Singh RK
Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
[TBL] [Abstract][Full Text] [Related]
45. Montelukast rescues primary neurons against Aβ1-42-induced toxicity through inhibiting CysLT1R-mediated NF-κB signaling.
Lai J; Mei ZL; Wang H; Hu M; Long Y; Miao MX; Li N; Hong H
Neurochem Int; 2014 Sep; 75():26-31. PubMed ID: 24879954
[TBL] [Abstract][Full Text] [Related]
46. Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury.
Zhou C; Shi X; Huang H; Zhu Y; Wu Y
Anesth Analg; 2014 May; 118(5):1090-6. PubMed ID: 24686047
[TBL] [Abstract][Full Text] [Related]
47. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
[TBL] [Abstract][Full Text] [Related]
48. BMP-7 Treatment Increases M2 Macrophage Differentiation and Reduces Inflammation and Plaque Formation in Apo E-/- Mice.
Singla DK; Singla R; Wang J
PLoS One; 2016; 11(1):e0147897. PubMed ID: 26824441
[TBL] [Abstract][Full Text] [Related]
49. Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.
Gupta S; Singh P; Sharma B
Curr Hypertens Rev; 2024; 20(1):23-35. PubMed ID: 38192137
[TBL] [Abstract][Full Text] [Related]
50. Effect of Montelukast on Bronchopulmonary Dysplasia (BPD) and Related Mechanisms.
Chen X; Zhang X; Pan J
Med Sci Monit; 2019 Mar; 25():1886-1893. PubMed ID: 30862773
[TBL] [Abstract][Full Text] [Related]
51. Pivotal role of serum- and glucocorticoid-inducible kinase 1 in vascular inflammation and atherogenesis.
Borst O; Schaub M; Walker B; Schmid E; Münzer P; Voelkl J; Alesutan I; Rodríguez JM; Vogel S; Schoenberger T; Metzger K; Rath D; Umbach A; Kuhl D; Müller II; Seizer P; Geisler T; Gawaz M; Lang F
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):547-57. PubMed ID: 25614279
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of EP4 signaling attenuates aortic aneurysm formation.
Yokoyama U; Ishiwata R; Jin MH; Kato Y; Suzuki O; Jin H; Ichikawa Y; Kumagaya S; Katayama Y; Fujita T; Okumura S; Sato M; Sugimoto Y; Aoki H; Suzuki S; Masuda M; Minamisawa S; Ishikawa Y
PLoS One; 2012; 7(5):e36724. PubMed ID: 22570740
[TBL] [Abstract][Full Text] [Related]
53. Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm.
Kaneko H; Anzai T; Takahashi T; Kohno T; Shimoda M; Sasaki A; Shimizu H; Nagai T; Maekawa Y; Yoshimura K; Aoki H; Yoshikawa T; Okada Y; Yozu R; Ogawa S; Fukuda K
Cardiovasc Res; 2011 Jul; 91(2):358-67. PubMed ID: 21436157
[TBL] [Abstract][Full Text] [Related]
54. Montelukast ameliorates streptozotocin-induced cognitive impairment and neurotoxicity in mice.
Zhang CT; Lin JR; Wu F; Ghosh A; Tang SS; Hu M; Long Y; Sun HB; Hong H
Neurotoxicology; 2016 Dec; 57():214-222. PubMed ID: 27702591
[TBL] [Abstract][Full Text] [Related]
55. Protective effects of selective mineralocorticoid receptor antagonist against aortic aneurysm progression in a novel murine model.
Kurobe H; Hirata Y; Matsuoka Y; Sugasawa N; Higashida M; Nakayama T; Maxfield MW; Yoshida Y; Shimabukuro M; Kitagawa T; Sata M
J Surg Res; 2013 Nov; 185(1):455-62. PubMed ID: 23731681
[TBL] [Abstract][Full Text] [Related]
56. [Effect of Galectin-9/Tim-3 pathway on the polarization of M1/M2 subtype in murine macrophages induced by lipopolysaccharide].
Zhang W; Zhang Y; Fang Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Sep; 30(9):836-841. PubMed ID: 30309408
[TBL] [Abstract][Full Text] [Related]
57. The cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast suppresses matrix metalloproteinase-13 expression induced by lipopolysaccharide.
Wei J; Chen S; Huang C; Guo W; Yang S; Feng B; Chu J
Int Immunopharmacol; 2018 Feb; 55():193-197. PubMed ID: 29268191
[TBL] [Abstract][Full Text] [Related]
58. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.
Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A
Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413
[TBL] [Abstract][Full Text] [Related]
59. Pharmacological inhibitor of notch signaling stabilizes the progression of small abdominal aortic aneurysm in a mouse model.
Cheng J; Koenig SN; Kuivaniemi HS; Garg V; Hans CP
J Am Heart Assoc; 2014 Oct; 3(6):e001064. PubMed ID: 25349182
[TBL] [Abstract][Full Text] [Related]
60. Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-κB pathway.
Tsai SH; Huang PH; Peng YJ; Chang WC; Tsai HY; Leu HB; Chen JW; Lin SJ
Cardiovasc Res; 2013 Dec; 100(3):501-10. PubMed ID: 24225494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
